Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Combined Hyperlipidemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Combined Hyperlipidemia. Displaying page 1 of 1.
    EudraCT Number: 2006-006328-20 Sponsor Protocol Number: HEL-C01-A Start Date*: 2008-06-03
    Sponsor Name:HELP Pharmaceuticals S.A.
    Full Title: A multicentre, randomised, double-blind, controlled with placebo clinical trial with parallel groups, for the evaluation of the efficacy and safety of combined treatment with L-carnitine and simvas...
    Medical condition: This study will evaluate the safety and efficacy of combined treatment with L- Carnitine and Simvastatin in reducing the Lipoprotein (a) and triglyceride level of patients with mixed hyperlipidemia...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003807-19 Sponsor Protocol Number: 0653A-071 Start Date*: 2004-12-21
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia
    Medical condition: Mixed hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027762 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006557-28 Sponsor Protocol Number: FENOPRA-III-06-1 Start Date*: 2007-05-07
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibr...
    Medical condition: Type 2 diabetic patients, as defined by the WHO without CVD and with CVD (Cardiovascular disease), with combined hyperlipidemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003237-16 Sponsor Protocol Number: GFT505-207-1 Start Date*: 2007-08-31
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, place...
    Medical condition: Patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001135-85 Sponsor Protocol Number: AROAPOC3-2003 Start Date*: 2022-09-06
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) PL (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000037-19 Sponsor Protocol Number: 0524B-024 Start Date*: 2008-07-15
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin...
    Medical condition: Mixed Hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) SE (Completed) GB (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-000688-57 Sponsor Protocol Number: AROAPOC3-2002 Start Date*: 2021-11-10
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005851-14 Sponsor Protocol Number: C LF0242780-01 05 02 Start Date*: 2007-03-19
    Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd
    Full Title: A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with m...
    Medical condition: Study in patients with mixed dyslipidemia (type IIb) at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-000515-15 Sponsor Protocol Number: C LF0242780-01 05 04 Start Date*: 2007-01-30
    Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd
    Full Title: A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg pravastatin monoth...
    Medical condition: Study in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg pravastatin alone.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027763 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000519-21 Sponsor Protocol Number: C LF0242780-01 05 03 Start Date*: 2006-06-29
    Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd
    Full Title: A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with atorvastatin monotherapy...
    Medical condition: Study in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 10 mg atorvastatin alone
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027763 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005185-36 Sponsor Protocol Number: FENOPRA-III-05-1 Start Date*: 2006-02-10
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: AN OPEN-LABEL PHASE III, STUDY TO EVALUATE THE SAFETY OF THE COMBINATION (FENOFIBRATE / PRAVASTATIN 160-40 MG) DURING 24 WEEKS, IN HIGH VASCULAR RISK PATIENTS WITH COMBINED HYPERLIPIDEMIA
    Medical condition: High vascular risk patients with combined hyperlipidemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-003029-11 Sponsor Protocol Number: 2012-489 Start Date*: 2012-09-10
    Sponsor Name:Steen Stender
    Full Title: Ethyl ester Versus Triglyceride formulations of long chained omega-3 fatty acids in moderate hypertriglyceridemia - a randomized placebo-controlled clinical trial (EVT)
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10071235 Combined hyperlipidemia LLT
    15.0 10010331 - Congenital, familial and genetic disorders 10060754 Type IV hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004799-21 Sponsor Protocol Number: KCT03/2012 Start Date*: 2013-02-21
    Sponsor Name:Krka, d.d., Novo mesto
    Full Title: The Efficacy and Safety of ROSUvastatin Dose Titration in the Treatment of PATients with Hyperlipidemia (ROSU-PATH)
    Medical condition: Patients with primary hypercholesterolemia and mixed dyslipidemia (type IIb)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10020604 Hypercholesterolemia LLT
    14.1 100000004861 10071235 Combined hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-002920-32 Sponsor Protocol Number: CRAD001HDE10 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: PRESERVATION OF RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH CERTICAN THERAPY: PROTECT Study A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of ...
    Medical condition: prophylaxis of organ rejections in adult patients after liver transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002889-11 Sponsor Protocol Number: D3560C00071 Start Date*: 2005-11-04
    Sponsor Name:AstraZeneca AB
    Full Title: An 18-Week, Randomized, Multicenter, Phase IIIb, Double-Blind, Crossover Study, Followed by an 18-Week Open-Label Period to Evaluate the Efficacy and Safety of the Lipid-Regulating Agents, Rosuvast...
    Medical condition: Dysbetalipoproteinemia (Fredrickson Type III Hyperlipoproteinemia)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2017-004983-37 Sponsor Protocol Number: FFIS-INM-2017-04 Start Date*: 2018-10-16
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
    Full Title: Multicenter, randomized, prospective study to establish the clinical efficacy and the mechanisms of tolerance following immunosuppression withdrawal in liver transplantation
    Medical condition: Hepatic transplant
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005532-18 Sponsor Protocol Number: PLX-CLI-03 Start Date*: 2017-01-02
    Sponsor Name:Pluristem Ltd.
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatmen...
    Medical condition: Critical Limb Ischemia (CLI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000441-38 Sponsor Protocol Number: CPCRA 065 Start Date*: 2005-04-26
    Sponsor Name:National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Full Title: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)
    Medical condition: HIV infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001979-70 Sponsor Protocol Number: IVA_01_337_HNAS_16_002 Start Date*: 2017-01-23
    Sponsor Name:Inventiva S.A.
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
    Medical condition: Nonalcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) AT (Completed) PT (Completed) ES (Completed) NL (Completed) PL (Completed) FR (Completed) BG (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022941-72 Sponsor Protocol Number: PMR-EC-1503 Start Date*: Information not available in EudraCT
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT ...
    Medical condition: Prophylaxis of heart transplant rejection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050432 Prophylaxis against heart transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA